A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN01941 in Healthy Volunteers
Latest Information Update: 04 Nov 2021
At a glance
- Drugs CRN 01941 (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Crinetics Pharmaceuticals
Most Recent Events
- 06 Apr 2020 According to an Crinetics Pharmaceuticals media release, the company has discontinued the development of CRN-01941 as Phase I data in healthy volunteers did not represent an improvement over paltusotine.
- 06 Apr 2020 Status changed from recruiting to discontinued, according to an Crinetics Pharmaceuticals media release.
- 13 Aug 2019 According to an Crinetics Pharmaceuticals media release, topline data from this trial is expceted in late 2019 or early 2020.